Assessing the overall benefit of a medication: cumulative benefit of secukinumab over time in patients with moderate-to-severe plaque psoriasis

Assessing the overall benefit of a medication: cumulative benefit of secukinumab over time in patients with moderate-to-severe plaque psoriasis

Background: Conventional measurements for assessing psoriasis treatment effects capture improvements at fixed, pre-specified timepoints, failing to account for cumulative clinical benefit over time. Objective: Explore the innovative concept of “cumulative clinical benefit” by examining the effect of...

Full description

Bibliographic Details
Main Authors: April W. Armstrong, Steven R. Feldman, Neil J. Korman, Xiangyi Meng, Adriana Guana, Judit Nyirady, Vivian Herrera, Yang Zhao
Format: Article
Language:English
Published: Taylor & Francis Group 2017-04-01
Series:Journal of Dermatological Treatment
Subjects:
biologics
cumulative clinical benefit
etanercept
interleukin-17a
psoriasis
secukinumab
Online Access:http://dx.doi.org/10.1080/09546634.2016.1214667

Similar Items

Similar Items